Delgocitinib Cream Shows Consistent CHE Efficacy Across Several Subgroups

A group of 4 studies at the Revolutionizing Atopic Dermatitis (RAD) 2026 Conference expand the evidence profile for delgocitinib cream (Anzupgo) in chronic hand eczema (CHE), demonstrating safety across 52 weeks in adults, superiority over topical PUVA in a matching-adjusted indirect comparison (MAIC), consistent efficacy regardless of prior systemic therapy exposure, and minimal systemic exposure with a favorable safety profile in adolescents.1,2,3,4

Delgocitinib Pooled Safety Data, MAIC vs PUVA, and Outcomes By Prior Therapy

The pooled safety analysis integrated data from DELTA 1, 2, 3, and DELTA FORCE, covering 944 delgocitinib-treated patients (291.31 patient-years) during the initial treatment period and 1040 patients (581.56 patient-years) during the as-needed treatment period through Week 52.

During the initial period, adverse event rates with delgocitinib were similar to cream vehicle and lower than with alitretinoin. The only adverse event of special interest during the as-needed period was a single non-serious case of eczema herpeticum in a patient with prior atopic dermatitis history. Application-site reactions occurred in less than 1% of delgocitinib-treated patients versus 2.4% with vehicle.1

In the MAIC comparing delgocitinib with topical PUVA plus as-required topical corticosteroids, using alitretinoin as the common anchor across DELTA FORCE and the ALPHA trial, delgocitinib was significantly more likely to achieve IGA-CHE/PGA 0/1 at week 12 (odds ratio, 2.5; 95% CI, 1.3-4.9; P = .009) and produced significantly greater HECSI improvement from baseline (difference, 13.4; 95% CI, 2.4-24.3; P = .017) and DLQI improvement (difference, 2.3; 95% CI, 0.6-4.1; P = .008) compared with PUVA.

In pooled analyses of DELTA 1 and DELTA 2 stratified by prior systemic therapy, delgocitinib cream significantly outperformed cream vehicle on IGA-CHE treatment success, HECSI-75, and HESD itch and pain improvement in both systemic-naïve (all P <.001) and systemic-experienced patients (all P≤ .002), with more pronounced differences in the systemic-naïve group.

Adolescent pharmacokinetics and safety: DELTA TEEN

DELTA TEEN was the first phase 3 trial of delgocitinib cream in adolescents aged 12 to less than 18 years with moderate-to-severe CHE. Systemic pharmacokinetic data showed geometric mean plasma concentrations of 0.28 ng/mL at week 8 and 0.22 ng/mL at week 16 (n=69 and n=66, respectively), with values remaining low and stable between the 2 timepoints, indicating no accumulation. Inestigators noted these concentrations were consistent with adult data from DELTA 2.

The overall incidence of adverse events was 50.0% with delgocitinib versus 16.7% with cream vehicle in DELTA TEEN; nasopharyngitis was the most common event in both groups (13.5% vs 16.7%).

All adverse events in the delgocitinib arm were non-serious, mild or moderate in severity, and not considered related to the drug. No clinically relevant changes in vital signs, laboratory parameters, or ECG findings were observed. Delgocitinib cream is under regulatory review for the adolescent indication.4

References

1. Bissonnette R, Agner T, Giménez-Arnau AM, et al. Safety of delgocitinib cream in adult patients with chronic hand eczema: pooled analysis of five phase 2b and phase 3 trials. Presented at: Revolutionizing Atopic Dermatitis; Nashville, TN; June 17-19, 2026.

2. Armstrong AW, Bewley A, Wollenberg A, et al. Matching-adjusted indirect comparison of the efficacy at week 12 of delgocitinib and topical PUVA in the treatment of severe chronic hand eczema. Presented at: Revolutionizing Atopic Dermatitis; Nashville, TN; June 17-19, 2026.

3. Bissonnette R, Schliemann S, Worm M, et al. Delgocitinib cream 20 mg/g for moderate to severe chronic hand eczema: outcomes over 16 weeks by prior systemic therapy exposure. Presented at: Revolutionizing Atopic Dermatitis; Nashville, TN; June 17-19, 2026.

4. Molin S, Baselga E, Navarro-Triviño FJ, et al. The DELTA TEEN phase 3 trial: systemic exposure and safety profile of delgocitinib cream in adolescents with moderate to severe chronic hand eczema. Presented at: Revolutionizing Atopic Dermatitis; Nashville, TN; June 17-19, 2026.